Heron Therapeutics, Inc. , a specialty pharmaceutical company, today announced an approximate one-quarter delay to the Company's timeline for the resubmission of the new drug application for Sustol to the U.S. Food and Drug Administration , the Company's product candidate for chemotherapy-induced nausea and vomiting .
http://ift.tt/1f6j4lY
http://ift.tt/1f6j4lY
No comments:
Post a Comment